These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 15831368

  • 1. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    Blanco S, Vaquero M, Gómez-Guerrero C, López D, Egido J, Romero R.
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
    [Abstract] [Full Text] [Related]

  • 2. Effects of antihypertensive drugs in experimental type 2 diabetes-related nephropathy.
    Blanco S, Penin R, Casas I, López D, Romero R.
    Kidney Int Suppl; 2002 Dec; (82):S27-31. PubMed ID: 12410851
    [Abstract] [Full Text] [Related]

  • 3. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G.
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity.
    Baylis C, Atzpodien EA, Freshour G, Engels K.
    J Pharmacol Exp Ther; 2003 Dec; 307(3):854-60. PubMed ID: 14560039
    [Abstract] [Full Text] [Related]

  • 5. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
    Zoja C, Corna D, Bruzzi I, Foglieni C, Bertani T, Remuzzi G, Benigni A.
    Exp Nephrol; 1996 Dec; 4(4):213-21. PubMed ID: 8983642
    [Abstract] [Full Text] [Related]

  • 6. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A.
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [Abstract] [Full Text] [Related]

  • 7. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes.
    Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J.
    Kidney Int; 2000 Jan; 57(1):167-82. PubMed ID: 10620198
    [Abstract] [Full Text] [Related]

  • 8. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats.
    Boor P, Celec P, Behuliak M, Grancic P, Kebis A, Kukan M, Pronayová N, Liptaj T, Ostendorf T, Sebeková K.
    Metabolism; 2009 Nov; 58(11):1669-77. PubMed ID: 19608208
    [Abstract] [Full Text] [Related]

  • 9. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
    Sebeková K, Lill M, Boor P, Heidland A, Amann K.
    Am J Nephrol; 2009 Nov; 29(3):164-70. PubMed ID: 18753741
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
    Perico N, Amuchastegui CS, Malanchini B, Bertani T, Remuzzi G.
    Exp Nephrol; 1994 Nov; 2(4):220-8. PubMed ID: 8069658
    [Abstract] [Full Text] [Related]

  • 11. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients.
    White KE, Bilous RW, Diabiopsies Study Group.
    Nephrol Dial Transplant; 2004 Jun; 19(6):1437-40. PubMed ID: 14993494
    [Abstract] [Full Text] [Related]

  • 12. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T, Honda T, Ohta S, Akashiba A, Takahashi T, Kameda T, Yoshii M, Minami J, Takahashi M, Ono H, Matsuoka H.
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [Abstract] [Full Text] [Related]

  • 13. Research into the glomerular podocyte--is it relevant to diabetic nephropathy?
    White KE.
    Diabet Med; 2006 Jul; 23(7):715-9. PubMed ID: 16842474
    [Abstract] [Full Text] [Related]

  • 14. Systemic evaluation of gene expression changes in major target organs induced by atorvastatin.
    Kato N, Liang YQ, Ochiai Y, Jesmin S.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):376-89. PubMed ID: 18295756
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Gross ML, El-Shakmak A, Szábó A, Koch A, Kuhlmann A, Münter K, Ritz E, Amann K.
    Diabetologia; 2003 Jun 28; 46(6):856-68. PubMed ID: 12802493
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis.
    Blanco S, Bonet J, López D, Casas I, Romero R.
    Kidney Int Suppl; 2005 Jan 28; (93):S10-4. PubMed ID: 15613060
    [Abstract] [Full Text] [Related]

  • 19. Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition.
    Sassy-Prigent C, Heudes D, Jouquey S, Auberval D, Belair MF, Michel O, Hamon G, Bariety J, Bruneval P.
    Lab Invest; 1995 Jul 28; 73(1):64-71. PubMed ID: 7603042
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.